Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

49 results about "Mitochondrial electron transport" patented technology

In eukaryotes, an important electron transport chain is found in the inner mitochondrial membrane where it serves as the site of oxidative phosphorylation through the action of ATP synthase. It is also found in the thylakoid membrane of the chloroplast in photosynthetic eukaryotes.

Green algae biological fuel cell generating power on basis of photosynthesis

The invention relates to a microbial fuel cell, in particular to a green algae biological fuel cell generating power on the basis of photosynthesis, which comprises a transparent cathode cell of green algae culture solution and an anode cell containing rich oxygen or oxidant solution, wherein the cathode cell and the anode cell are isolated by a proton exchange membrane; the cathode and anode of the cell are fixed in the cathode cell and the anode cell respectively; the cathode cell is isolated from the air to create an anaerobic environment in the cathode cell, hydrogen-generating green algae is used a system green algae material, an indirect-process hydrogen generation regulating technique is adopted, an electronic transfer mediator is added into the system to enable electrons which aregenerated by photosynthesis to be combined with the electronic mediator through an electron transport chain before reaching hydrogenase, the electronic mediator releases electrons at a cathode electrode, and the electrons are transferred to the anode to combine with protons passing through the proton exchange membrane and oxidant in the cathode cell to form water. In the invention, optical energycan be converted into electric energy by coupling the photosynthesis of microalgae and a cell system, and a novel biological fuel cell is provided.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI

Use of mitochondrial activity inhibitors for the treatment of poor prognosis acute myeloid leukemia

A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need thereof an effective amount of a mitochondrial activity inhibitor, for example a classA electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and / or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, normal karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and / or abnormal chromosome (5 / 7), and / or a high leukemic stem cell (LSC) frequency.
Owner:UNIV DE MONTREAL

Exosome assay for depression and psychosis and methods and agents for treating depression, psychosis and schizophrenia

The present disclosure relates to exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers and diagnostic and prognostic methods for depression, psychosis and schizophrenia. The disclosure also provides compositions for detecting exosomal complement mediators, cytokines, and mitochondrial electron transport biomarkers in biological samples as well as compositions and methods useful for treating depression, psychosis and schizophrenia.
Owner:GOETZL EDWARD J

PH/ROS response type nano-drug delivery system and preparation method

The invention discloses a pH / ROS responsive nano-drug delivery system and a preparation method thereof. MPEG-NH2 and Cbz-Lys-NCA are mainly used as raw materials for polymerization to form a prodrug skeleton, alpha-TOS and D (Boc) are used as carriers for synthesis of a polymer, DMA and the skeleton are conjugated, the polymer skeleton is modified by pHLIP, DOX is entrapped, pHLIP is modified on the polymer skeleton, and an anti-cancer drug is entrapped in the polymer skeleton. By integrating DMA and pHLIP, pH responsiveness and charge reversal to a tumor microenvironment are realized, and cellular uptake is promoted. The TOS is combined to a polymer, so that a mitochondrial electron transport chain is blocked, rapid generation of ROS is achieved, release of drugs and more TOS is promoted, and positive feedback release of the drugs is formed; and therefore, the killing effect on tumors is realized by releasing the wrapped anti-cancer drug; moreover, through the unique pH / ROS double-response type characteristic, stability can be kept in the blood circulation environment, drug release is increased in the tumor microenvironment, targeted drug release is achieved, targeted uptake of tumor cells to drugs can be improved, and the more efficient tumor killing effect is achieved.
Owner:NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products